Diclofenac inhibits both COX-1 and COX-2, but it is significantly more potent against COX-2. In lab testing, the concentration of diclofenac needed to suppress COX-1 activity by half is roughly 29 times the concentration needed to suppress COX-2 by the same amount. That ratio is nearly identical to celecoxib (30), the most widely prescribed dedicated COX-2 inhibitor. So while diclofenac is traditionally classified as a “non-selective” NSAID, its actual behavior sits much closer to the COX-2 selective category than drugs like ibuprofen or naproxen.
What COX-2 Selectivity Actually Means
Your body produces two versions of the cyclooxygenase enzyme. COX-1 is active all the time and helps maintain the protective lining of your stomach and supports normal blood clotting. COX-2 ramps up in response to injury or inflammation and drives pain, swelling, and fever. Most traditional painkillers like ibuprofen and naproxen block both enzymes at roughly similar concentrations, which is why they relieve pain but can also irritate the stomach.
COX-2 selectivity is measured as a ratio: how much more drug is required to block COX-1 compared with COX-2. A ratio greater than 1 means the drug hits COX-2 harder. Diclofenac’s ratio of 29 places it far above ibuprofen and naproxen, which sit near or below 1. It falls short of highly selective agents like rofecoxib (withdrawn from the market), which showed roughly 20-fold greater selectivity than diclofenac. But in practical terms, diclofenac and celecoxib look remarkably similar on paper.
Why It’s Still Called “Non-Selective”
The classification dates back to a time when regulators drew a hard line between traditional NSAIDs and the newer “coxib” drugs designed from the ground up to spare COX-1. Diclofenac was already on the market as a conventional NSAID long before COX-2 selectivity became a selling point, so it was grouped with ibuprofen and naproxen by default. Researchers now view selectivity as a spectrum rather than a simple yes-or-no category, and diclofenac consistently lands in the middle, well above traditional NSAIDs but below the most selective coxibs.
At a standard 50 mg dose taken three times daily, diclofenac achieves over 90% inhibition of COX-2 over the eight hours after dosing while only partially inhibiting COX-1 (about 50%). That gap narrows at higher doses, though, which is why some older classification tables list it among drugs whose COX-2 preference can diminish when the dose climbs.
How This Affects Your Stomach
Because COX-1 helps maintain the stomach’s protective mucus layer, drugs that strongly block it tend to cause more ulcers and GI bleeding. Diclofenac’s partial sparing of COX-1 gives it a measurable advantage over truly non-selective NSAIDs in this area. In network meta-analyses, rates of major upper GI events with diclofenac were about 50% to 70% lower than with naproxen or ibuprofen.
That said, diclofenac is not as gentle on the stomach as the most selective COX-2 inhibitors. In the large SUCCESS-1 trial, patients taking naproxen or diclofenac had significantly more ulcer complications than those on celecoxib (when neither group was also taking aspirin). And in a head-to-head comparison with etoricoxib (another coxib), upper GI events were about 31% more common with diclofenac. One practical workaround: a trial of 287 arthritis patients found that combining diclofenac with a proton pump inhibitor (a common acid-reducing medication) produced recurrent ulcer bleeding rates similar to those seen with celecoxib alone.
Cardiovascular Risk Mirrors True COX-2 Inhibitors
COX-2 selectivity comes with a trade-off. Blocking COX-2 reduces a substance called prostacyclin that helps keep blood vessels relaxed and discourages clotting, while leaving COX-1’s clot-promoting effects intact. This imbalance is why COX-2 selective drugs raise cardiovascular risk, and diclofenac is no exception.
A large series of nationwide emulated trials found that diclofenac carried a 20% higher rate of major cardiovascular events (heart attack, stroke, or cardiac death) compared with older COX-2 preferential drugs like meloxicam and etodolac. When compared directly to celecoxib and etoricoxib, the rates were essentially the same. The risk was most pronounced in women, in people who already had elevated cardiovascular risk, and at higher doses. This cardiovascular profile is the reason diclofenac now carries the same boxed warning as dedicated COX-2 inhibitors.
How Diclofenac Compares for Pain Relief
Despite the safety nuances, diclofenac remains one of the more effective oral anti-inflammatory options. At 150 mg per day, it outperformed celecoxib (200 mg/day), naproxen (1,000 mg/day), and ibuprofen (2,400 mg/day) for pain relief in patients with osteoarthritis or rheumatoid arthritis. At a lower dose of 100 mg per day, it was comparable to all of them. Patients on diclofenac were also less likely to stop treatment due to lack of efficacy compared with celecoxib, ibuprofen, or acetaminophen.
Diclofenac’s COX-2 inhibition appears to concentrate at inflamed tissues like joint fluid and joint capsules, which may help explain why it performs well for joint-related pain conditions even at moderate doses. This tissue-level selectivity is distinct from the whole-blood assays used to generate the selectivity ratios, and it highlights why lab numbers don’t always translate neatly into clinical experience.
The Bottom Line on Classification
Diclofenac sits in a gray zone. Its COX-2 selectivity ratio is virtually identical to celecoxib’s in lab assays. Its cardiovascular risk profile matches that of dedicated coxibs. Its GI profile falls between traditional NSAIDs and the most selective COX-2 inhibitors. Calling it “non-selective” understates its COX-2 preference, but calling it a true COX-2 inhibitor overstates the picture at higher doses where COX-1 inhibition increases. The most accurate description is that diclofenac is a preferential COX-2 inhibitor, behaving more like celecoxib than like ibuprofen in most clinically meaningful ways.